After a cessation of almost 40 years, there is renewed interest into therapeutic applicationsof the serotonergic psychedelic psilocybin for the treatment of patients with various psychiatric disorders. PubMed was searched for clinical trials into "psilocybin" between 2000 and 2020, complemented by handsearching. Articles were also screened for explanatory mo...
After a cessation of almost 40 years, there is renewed interest into therapeutic applicationsof the serotonergic psychedelic psilocybin for the treatment of patients with various psychiatric disorders. PubMed was searched for clinical trials into "psilocybin" between 2000 and 2020, complemented by handsearching. Articles were also screened for explanatory mo...
Back to table of contents Previous article Next article ViewpointsFull AccessWait for the Science Before Widespread Use of PsilocybinNicole Harrington Cirino, M.D.Nicole Harrington Cirino, M.D.Published Online:28 Sep 2020https://doi.org/10.1176/appi.pn.2020.10a32AbstractThe momentum behind psilocybin as the next big "breakthrough" in treating psychiatric dis...
cancer patient: cancer patientWith the technological advances that have been made in diagnostics for cancer, more disease is being detected at an earlier stage. Although this generally improves the patient's chances for survival, a diagnosis of cancer can often provoke significant psychological distress in patients. A significant number of cancer patients wi...
ObjectiveThe authors provide an evidenced-based summary of the literature on the clinical application of psychedelic drugs in psychiatric disorders.MethodsSearches of PubMed and PsycINFO via Ovid were conducted for articles in English, in peer-reviewed journals, reporting on "psilocybin," "lysergic acid diethylamide," "LSD," "ayahuasca," "3,4-methylenedioxym...
Though there was initial interest in the use of psychedelic drugs for psychiatric treatment, bad outcomes and subsequent passage of the Substance Act of 1970, which placed psychedelic drugs in the Schedule I category, significantly limited potential progress. More recently, however, there has been renewal in interest and promise of psychedelic research. The ...
In a recent issue of the BMC Psychiatry, the evidence of effectiveness of treatments for psychiatric conditions in end-stage cancer patients was reviewed (Johnson, 2018). The review was comprehensive, and included traditional and non-traditional/alternative treatments, including herbal medicines and spirituality. However, evidence showing that classic or ser...
Back to table of contents Previous article Next article Full AccessPsychedelic Medicine: Careful Studies, Regulations Are the AnswerPaul SummergradM.D.Paul SummergradSearch for more papers by this authorM.D.Published Online:30 Apr 2019https://doi.org/10.1176/appi.pn.2019.5a25AbstractPaul Summergrad, M.D., is the Dr. Frances S. Arkin Professor and Chair of th...
RationaleMicrodosing psychedelics-the regular consumption of small amounts of psychedelic substances such as LSD or psilocybin-is a growing trend in popular culture. Recent studies on full-dose psychedelic psychotherapy reveal promising benefits for mental well-being, especially for depression and end-of-life anxiety. While full-dose therapies include percep...
The purpose of this paper is to provide an integrative review and offer novel insights regarding human research with classic psychedelics (classic hallucinogens), which are serotonin 2A receptor (5-HT2AR) agonists such as lysergic acid diethylamide (LSD), mescaline, and psilocybin. Classic psychedelics have been administered as sacraments since ancient times...
Microdosing psychedelics - the regular consumption of small amounts of psychedelic substances such as LSD or psilocybin - is a growing trend in popular culture. Recent studies on full-dose psychedelic psychotherapy reveal promising benefits for mental well-being, especially for depression and end-of-life anxiety. While full-dose therapies include perception-...
Microdosing psychedelics - the regular consumption of small amounts of psychedelic substances such as LSD or psilocybin - is a growing trend in popular culture. Recent studies on full-dose psychedelic psychotherapy reveal promising benefits for mental well-being, especially for depression and end-of-life anxiety. While full-dose therapies include perception-...
Psilocybin is a psychoactive compound with clinical applications produced by dozens of mushroom species 1. There has been a longstanding interest in psilocybin research with regard to treatment for addiction 2, depression 3, and end-of-life suffering 4. However, until recently very little was known about psilocybin biosynthesis and its ecological role. Here ...
BackgroundPsychiatric research in the 1950s and 1960s showed potential for psychedelic medications to markedly alleviate depression and suffering associated with terminal illness. More recent published studies have demonstrated the safety and efficacy of psilocybin, MDMA, and ketamine when administered in a medically supervised and monitored approach. A sing...
Recent clinical trials have shown promising results in the use of psilocybin and MDMA-assisted psychotherapy to alleviate end-of-life anxiety in those life-threatening illnesses or experiencing end-of-life anxiety. This session will share some of those results. Below are links to the qualitative paper shared at the conference, as well as two short videos of ...
BackgroundPsilocybin is a serotonin receptor agonist that occurs naturally in some mushroom species. Recent studies have assessed the therapeutic potential of psilocybin for various conditions, including end-of-life anxiety, obsessive-compulsive disorder, and smoking and alcohol dependence, with promising preliminary results. Here, we aimed to investigate th...
